Women's Health Initiative Sight Examination (WHISE)

This substudy phs000503 WHISE contains phenotypes only for the Sight Examination study. Summary level phenotypes for the WHI Cohort study participants can be viewed at the top-level study page phs000200 WHI Cohort. Individual level phenotype data and molecular data for all WHI top-level study and substudies are available by requesting Authorized Access to the WHI Cohort study phs000200.

Women enrolled in the Women's Health Initiative (WHI) Hormone Replacement Therapy (HRT) Clinical Trial (CT) were included in this study. In WHI, participants who did not have a hysterectomy before enrollment into the WHI HRT CT were randomly assigned to either conjugated equine estrogens with progestin (CEE P) (0.625 mg/d of CEE and 2.5 mg/d of progestin) or a placebo. Those without a uterus were randomly assigned to either CEE (0.625 mg/d) or a placebo. Participants in the WHISE Study were recruited an average of 5.1 years after randomization into the WHI HRT CT. Participants included 4688 women who consented to participate in the WHISE Study; 4347 completed enrollment with photographs of at least 1 eye. The purpose of the study was to evaluate the effects of HRT on age-related macular degeneration.

• Study Design:
  • Clinical Trial
• Study Type:
  • Randomized
  • Double-Blind
  • Clinical Trial
• Total number of consented subjects: 3031
• Subject Sample Telemetry Report (SSTR)

• PubMed

Inclusion Criteria

1. Women aged 65 years or older enrolled in the WHI HRT Clinical Trial.
2. Speak and read English or Spanish, agree to complete study questionnaires and two eye examinations with fundus photography, and sign the informed consent document
3. Patient has at least one eye that can be dilated for the purpose of retinal fundus photography

Exclusion Criteria

1. Allergies to dilating eye drops
2. Other known contraindications for the administration of dilating eye drops
3. Any reason that the participant cannot be subjected to retinal fundus photography

• Primary Phenotype: Macular Degeneration
• Wet Macular Degeneration
• Geographic Atrophy

• Principal Investigator
  • Mary N. Haan, PhD. Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA.